Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Solip, Park
  • Espinosa-Carrasco, José
  • Ortiz-Martínez, Daniel
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  • Toledano, Ignasi
  • Supek, Fran
  • Lehner, Ben
Premature termination codons (PTCs) cause ~10-20% of inherited diseases and are a major mechanism of tumor suppressor gene inactivation in cancer. A general strategy to alleviate the effects of PTCs would be to promote translational readthrough. Nonsense suppression by small molecules has proven effective in diverse disease models, but translation into the clinic is hampered by ineffective readthrough of many PTCs. Here we directly tackle the challenge of defining drug efficacy by quantifying the readthrough of ~5,800 human pathogenic stop codons by eight drugs. We find that different drugs promote the readthrough of complementary subsets of PTCs defined by local sequence context. This allows us to build interpretable models that accurately predict drug-induced readthrough genome-wide, and we validate these models by quantifying endogenous stop codon readthrough. Accurate readthrough quantification and prediction will empower clinical trial design and the development of personalized nonsense suppression therapies., Work in the Supek laboratory was supported by an ERC StG ‘HYPER-INSIGHT’ (757700) and ERC CoG ‘STRUCTOMATIC’ (101088342), Horizon2020 project ‘DECIDER’ (965193), Horizon Europe project ‘LUCIA’ (101096473), Spanish government project ‘REPAIRSCAPE’, CaixaResearch project ‘POTENT-IMMUNO’ (HR22-00402), an ICREA professorship to F.S., the SGR funding from the Catalan government and a Novo Nordisk Fonden starting package. Work in the Lehner laboratory was funded by European Research Council (ERC) Advanced (grant 883742) and Consolidator (grant 616434), the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Center of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322) and the CERCA Program/Generalitat de Catalunya. The authors would like to thank the four members E. Ramírez, A. Bote, E. Julià and Ò. Fornàs of the Flow Cytometry CRG Core Unit for their support and time, together with G. Palou (IRB) for his help in retrieving the transcript sequences from the Ensembl database and all members of the Supek and Lehner laboratories for helpful discussions and suggestions.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya. We thank Solip Park for method consultations, comments, and discussions.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya. We thank Solip Park for method consultations, comments, and discussions.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The impact of rare germline variants on human somatic mutation processes

  • Vali-Pour, Mischan
  • Solip, Park
  • Espinosa-Carrasco, José
  • Ortiz-Martínez, Daniel
  • Lehner, Ben, 1978-
  • Supek, Fran
Somatic mutations are an inevitable component of ageing and the most important cause of cancer. The rates and types of somatic mutation vary across individuals, but relatively few inherited influences on mutation processes are known. We perform a gene-based rare variant association study with diverse mutational processes, using human cancer genomes from over 11,000 individuals of European ancestry. By combining burden and variance tests, we identify 207 associations involving 15 somatic mutational phenotypes and 42 genes that replicated in an independent data set at a false discovery rate of 1%. We associate rare inherited deleterious variants in genes such as MSH3, EXO1, SETD2, and MTOR with two phenotypically different forms of DNA mismatch repair deficiency, and variants in genes such as EXO1, PAXIP1, RIF1, and WRN with deficiency in homologous recombination repair. In addition, we identify associations with other mutational processes, such as APEX1 with APOBEC-signature mutagenesis. Many of the genes interact with each other and with known mutator genes within cellular sub-networks. Considered collectively, damaging variants in the identified genes are prevalent in the population. We suggest that rare germline variation in diverse genes commonly impacts mutational processes in somatic cells., M.V.P. was supported by a Spanish Ministry of Science and Innovation FPI Fellowship (ref.: PRE2018-084410). Work in the lab of B.L. is funded by European Research Council (ERC) Advanced (883742) and Consolidator (616434) grants, the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Centre of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322), and the CERCA Program/Generalitat de Catalunya. Work in the lab of F.S. is funded by the ERC Starting Grant HYPER-INSIGHT (757700), the Horizon2020 RIA grant DECIDER (965193), Spanish Ministry of Science and Innovation grant REPAIRSCAPE (PID2020-118795GB-I00), the EMBO YIP program, the Severo Ochoa Centre of Excellence award to IRB Barcelona, and the CERCA Program/Generalitat de Catalunya.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Genome-scale quantification and prediction of pathogenic stop codon readthrough by small molecules

  • Toledano, Ignasi
  • Supek, Fran
  • Lehner, Ben
Premature termination codons (PTCs) cause ~10-20% of inherited diseases and are a major mechanism of tumor suppressor gene inactivation in cancer. A general strategy to alleviate the effects of PTCs would be to promote translational readthrough. Nonsense suppression by small molecules has proven effective in diverse disease models, but translation into the clinic is hampered by ineffective readthrough of many PTCs. Here we directly tackle the challenge of defining drug efficacy by quantifying the readthrough of ~5,800 human pathogenic stop codons by eight drugs. We find that different drugs promote the readthrough of complementary subsets of PTCs defined by local sequence context. This allows us to build interpretable models that accurately predict drug-induced readthrough genome-wide, and we validate these models by quantifying endogenous stop codon readthrough. Accurate readthrough quantification and prediction will empower clinical trial design and the development of personalized nonsense suppression therapies., Work in the Supek laboratory was supported by an ERC StG ‘HYPER-INSIGHT’ (757700) and ERC CoG ‘STRUCTOMATIC’ (101088342), Horizon2020 project ‘DECIDER’ (965193), Horizon Europe project ‘LUCIA’ (101096473), Spanish government project ‘REPAIRSCAPE’, CaixaResearch project ‘POTENT-IMMUNO’ (HR22-00402), an ICREA professorship to F.S., the SGR funding from the Catalan government and a Novo Nordisk Fonden starting package. Work in the Lehner laboratory was funded by European Research Council (ERC) Advanced (grant 883742) and Consolidator (grant 616434), the Spanish Ministry of Science and Innovation (BFU2017-89488-P, EMBL Partnership, Severo Ochoa Center of Excellence), the Bettencourt Schueller Foundation, the AXA Research Fund, Agencia de Gestio d’Ajuts Universitaris i de Recerca (AGAUR, 2017 SGR 1322) and the CERCA Program/Generalitat de Catalunya. The authors would like to thank the four members E. Ramírez, A. Bote, E. Julià and Ò. Fornàs of the Flow Cytometry CRG Core Unit for their support and time, together with G. Palou (IRB) for his help in retrieving the transcript sequences from the Ensembl database and all members of the Supek and Lehner laboratories for helpful discussions and suggestions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mutational signatures are markers of drug sensitivity of cancer cells

  • Levatić, Jurica
  • Salvadores, Marina|||0000-0002-7850-7691
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Supek, Fran
Genomic analyses have revealed mutational footprints associated with DNA maintenance gone awry, or with mutagen exposures. Because cancer therapeutics often target DNA synthesis or repair, we asked if mutational signatures make useful markers of drug sensitivity. We detect mutational signatures in cancer cell line exomes (where matched healthy tissues are not available) by adjusting for the confounding germline mutation spectra across ancestries. We identify robust associations between various mutational signatures and drug activity across cancer cell lines; these are as numerous as associations with established genetic markers such as driver gene alterations. Signatures of prior exposures to DNA damaging agents - including chemotherapy - tend to associate with drug resistance, while signatures of deficiencies in DNA repair tend to predict sensitivity towards particular therapeutics. Replication analyses across independent drug and CRISPR genetic screening data sets reveal hundreds of robust associations, which are provided as a resource for drug repurposing guided by mutational signature markers.